Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: A report of two casesHASAN, Syed; HASSAN, Mohamed; OKE, Luc et al.Journal of the National Medical Association. 2003, Vol 95, Num 12, pp 1208-1210, issn 0027-9684, 3 p.Article

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disordersTSIMBERIDOU, Apostolia M; COLBURN, Dawn E; WELCH, Mary Alma et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 3, pp 229-234, issn 0344-5704, 6 p.Article

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitroHOUGHTON, Peter J; GERMAIN, Glen S; HARWOOD, Franklin C et al.Cancer research (Baltimore). 2004, Vol 64, Num 7, pp 2333-2337, issn 0008-5472, 5 p.Article

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndromeCORTES, Jorge; AULT, Patricia; KOLLER, Charles et al.Blood. 2003, Vol 101, Num 12, pp 4714-4716, issn 0006-4971, 3 p.Article

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyCORTES, Jorge E; TALPAZ, Moshe; FERRAJOLI, Allessandra et al.Blood. 2003, Vol 101, Num 10, pp 3794-3800, issn 0006-4971, 7 p.Article

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571PREJZNER, W; KNOPINSKA-POSŁUSZNY, W; MIKOŁAJCZUK, J et al.Clinical and laboratory haematology. 2003, Vol 25, Num 5, pp 293-296, issn 0141-9854, 4 p.Article

Position paper on imatinib mesylate in chronic myeloid leukaemiaO'BRIEN, Stephen G; RULE, Simon A. J.British journal of haematology. 2002, Vol 119, Num 1, pp 268-272, issn 0007-1048Article

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivationMATEI, Daniela; CHANG, David D; JENG, Meei-Huey et al.Clinical cancer research. 2004, Vol 10, Num 2, pp 681-690, issn 1078-0432, 10 p.Article

Chronic myeloid leukemia patients resistant to or intolerant of interferon α and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemiaSTEEGMANN, Juan Luis; MORENO, Gemma; MUNOZ, Cecilia et al.Haematologica (Roma). 2003, Vol 88, Num 7, pp 762-768, issn 0390-6078, 7 p.Article

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AMLKINDLER, Thomas; BREITENBUECHER, Frank; MARX, Andreas et al.Blood. 2003, Vol 101, Num 8, pp 2960-2962, issn 0006-4971, 3 p.Article

Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell lineKOTAKI, Mitsuko; MOTOJI, Toshiko; TAKANASHI, Minoko et al.Cancer letters. 2003, Vol 199, Num 1, pp 61-68, issn 0304-3835, 8 p.Article

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib mechanisms, successes, and challenges to rational drug developmentDEMETRI, George D.Hematology/oncology clinics of North America. 2002, Vol 16, Num 5, issn 0889-8588, vii, 1115-1124 [11 p.]Article

Imatinib alone and in combination for chronic myeloid leukemiaDRUKER, Brian J.Seminars in hematology. 2003, Vol 40, Num 1, pp 50-58, issn 0037-1963, 9 p.Article

Imatinib mesylate (Gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitroDZIBA, Joshua M; AIN, Kenneth B.The Journal of clinical endocrinology and metabolism. 2004, Vol 89, Num 5, pp 2127-2135, issn 0021-972X, 9 p.Article

Imatinib mesylate efficiently achieves Therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancerWOLFF, Nicholas C; RANDLE, Dwight E; EGORIN, Merrill J et al.Clinical cancer research. 2004, Vol 10, Num 10, pp 3528-3534, issn 1078-0432, 7 p.Article

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controlsKANTARJIAN, Hagop; O'BRIEN, Susan; KORNBLAU, Steven et al.Clinical cancer research. 2004, Vol 10, Num 1, pp 68-75, issn 1078-0432, 8 p., 1Article

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progressionMARKTEL, Sarah; MARIN, David; OLAVARRIA, Eduardo et al.Haematologica (Roma). 2003, Vol 88, Num 3, pp 260-267, issn 0390-6078, 8 p.Article

Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistanceMARCUCCI, Guido; PERROTTI, Danilo; CALIGIURI, Michael A et al.Clinical cancer research. 2003, Vol 9, Num 4, pp 1248-1252, issn 1078-0432, 5 p.Article

Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patientsCERVANTES, Francisco; HERNANDEZ-BOIUDA, Juan-Carlos; ODRIOZOIA, Jesus et al.Haematologica (Roma). 2003, Vol 88, Num 10, pp 1117-1122, issn 0390-6078, 6 p.Article

Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitroOEHLER, Leopold; JAEGER, Eva; ESER, Alexander et al.Blood. 2003, Vol 102, Num 6, pp 2240-2242, issn 0006-4971, 3 p.Article

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemiaVAN DEVENTER, Hendrik W; HALL, Melissa D; ORLOWSKI, Robert Z et al.American journal of hematology. 2002, Vol 71, Num 3, pp 184-190, issn 0361-8609, 7 p.Article

Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapyHASFORD, J; PFIRRMANN, M; HEHLMANN, R et al.Seminars in hematology. 2003, Vol 40, Num 1, pp 4-12, issn 0037-1963, 9 p.Article

A randomized multicenter open label phase ii study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph⁺/BCR-ABL⁺) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)WASSMANN, B; GÖKBUGET, N; SCHEURING, U. J et al.Annals of hematology (Print). 2003, Vol 82, Num 11, pp 716-720, issn 0939-5555, 5 p.Article

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agentsPANDIELLA, Atanasio; CARVAJAL-VERGARA, Xonia; TABERA, Soraya et al.British journal of haematology. 2003, Vol 123, Num 5, pp 858-868, issn 0007-1048, 11 p.Article

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibCORBIN, Amie S; LA ROSEE, Paul; STOFFREGEN, Eric P et al.Blood. 2003, Vol 101, Num 11, pp 4611-4614, issn 0006-4971, 4 p.Article